FDA Clearance Tracker · P090031-S009
Monovisc
Last checked: Nov 20, 2026Latest source record: Jan 9, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Jan 9, 2020
Approved
Time to decision
174 days
Received Jul 19, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P090031-S009
- Device name
- Monovisc
- Applicant
- Anika Therapeutics, Inc.
- Applicant location
- Beford, MA
- Received
- Jul 19, 2019
- Decided
- Jan 9, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P090031
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
Approval for inclusion of new clinical evidence in the labeling (Information for Prescribers) for Monovisc.
Source documents
Other decisions for Anika Therapeutics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261869 · Decided Sep 17, 2026 · 105 days after receipt
Device type: Fastener, Fixation, Nondegradable, Soft Tissue (MBI) · Orthopedic Surgery
- HYALOMATRIX510(k)
K261311 · Decided Sep 2, 2026 · 134 days after receipt
Device type: Absorbable Synthetic Wound Dressing (QSZ) · General & Plastic Surgery
- Integrity Implant510(k)
K250997 · Decided Jun 17, 2025 · 77 days after receipt
Device type: Mesh, Surgical, Non-Absorbable, Orthopaedics, Reinforcement Of Tendon (OWX) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.